# Moderna Shares Gain 11.04% Ahead of Melanoma Trial Data By Enna Lee Canonical URL: https://www.tokenpost.com/news/investing/36860 Published: 2026-10-21T17:06:53.000Z Updated: 2026-10-21T17:06:53.000Z Section: Investing > The stock closed at $242.08 on Oct. 20, about 284.5% above its Aug. 18 close, as investors await detailed Phase 3 results. Moderna (MRNA) shares climbed 11.04% over two sessions, closing at $242.08 on Oct. 20, as investors awaited detailed Phase 3 results for its melanoma treatment with Merck. The stock gained 4.07% on Oct. 19 and 6.69% on Oct. 20. At the latest close, shares were about 284.5% above their $62.96 close on Aug. 18, the trading day before the companies announced initial trial results. The Phase 3 INTerpath-001 trial tests intismeran autogene, an investigational personalized mRNA therapy, with Merck’s Keytruda in patients whose high-risk, stage IIB–IV cutaneous melanoma had been completely removed by surgery. On Aug. 19, Moderna and Merck said the combination met the study’s main goal for recurrence-free survival and a key secondary goal for distant metastasis-free survival. The two-session rise followed a [7.82% decline on Oct. 16](). Detailed trial results are scheduled for presentation Saturday, Oct. 24, at 10:30 a.m. ET (14:30 UTC) during the European Society for Medical Oncology congress. Moderna has also scheduled an investor event for 1 p.m. ET (17:00 UTC) that day. ## Links in this article - [7.82% decline on Oct. 16](https://www.tokenpost.com/news/investing/33686)